As different combinations of HLA ligands and KIR receptors in HCC have been shown to produce a different responses to treatment with anti-PD-1 immunotherapies in patients with virus-related HCC compared to non-alcoholic steatohepatitis (NASH) or controls, data had supported this concept [57]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.